all report title image
  • Published On : Oct 2018
  • Code : CMI2251
  • Industry : Pharmaceutical
  • Pages : 165
  • Formats :

Calciphylaxis Treatment Market – Insights

Calciphylaxis or Calcific Uremic Arteriolopathy (CUA) is the most severe form of cardiovascular calcification in dialysis patients. It starts with a calcification of small peripheral vessels and quickly spreads in the body. Moreover, people suffering from calciphylaxis have an imbalance in calcium metabolism, which causes calcium to be deposited in arterioles, which eventually leads to the formation of blood clots in the arterioles. Blood clots can cause fat tissues and skin to be deprived of oxygen and nourishment.

According to a data published by National Center for Biotechnology Information (NCBI) 2014 report, calciphylaxis affects around 4% of patients in the late stage of chronic kidney disease and 55% of patients with calciphylaxis die within a year of diagnosis and suffer from painful skin ulcers and a high risk of infection. No effective treatment for calciphylaxis is currently available and its causes are unknown. However, patients suffering from this disease are usually treated with intensive care, including wound management. The occurrence of calciphylaxis is associated with hyperthyroidism.

The global calciphylaxis treatment market size was valued at US$ 1,097.7 million in 2017 and is expected to witness a CAGR of 9.6% over the forecast period (2018 – 2026).

Global Calciphylaxis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%)

Calciphylaxis Treatment  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2018)

Increasing clinical trials in the field of calciphylaxis is expected to drive the calciphylaxis treatment market revenue

According to the Journal of General Internal Medicine 2014 study, calciphylaxis has an increasing incidence trend and a 50% mortality rate within the first year of onset. High prevalence of kidney disease is a major factor for incidences of calciphylaxis. According to the National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center, in 2016, over 661,000 Americans had kidney failure and 468,000 of these patients were on dialysis.

Various academic research institutes and companies are focused on developing suitable treatment for calciphylaxis. For instance in March 2018, Sanifit successfully completed a Phase II trial of the first effective treatment for calciphylaxis. Moreover, in 2014, researchers at the National Kidney Foundation reported successful application of intravenous (IV) pamidronate to treat calciphylaxis in patients with End-Stage Renal Disease (ESRD).

Calciphylaxis Treatment Market Restraints

Lack of an appropriate treatment for calciphylaxis is a major factor hindering growth of the global calciphylaxis treatment market. However, increasing research to develop a suitable treatment for the condition is expected to drive growth of the market.

Calciphylaxis Treatment Market - Regional Insights

On the basis of region, the global calciphylaxis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America calciphylaxis treatment market is expected to foresee major revenue share, owing to increasing government support and funding to treat calciphylaxis patients. According to the National Kidney Disease Education Program study 2015, in the U.S., treatment of chronic kidney disease surpasses US$ 48 billion, annually and the ESRD program consumes 6.7% of the total Medicare budget to care for less than 1% of the covered population.

Asia Pacific calciphylaxis treatment market is expected to witness growth at a significant CAGR, owing to increasing expenditure in treatment of kidney diseases coupled with high prevalence of kidney diseases with diabetes and growing geriatric population base. For instance, according to the National Kidney Disease Education Program study 2015, in Australia, treatment for all current and new cases of kidney failure by 2020 is expected to cost around US$ 12 billion. Moreover, annual cost of dialysis per patient, annually varies between US $35,000 and 55,000 depending on the type of treatment.

Global Calciphylaxis Treatment Market Share (%) Analysis, By Region 2017

Calciphylaxis Treatment  | Coherent Market Insights   

 Source: Coherent Market Insights Analysis (2018)

Calciphylaxis Treatment Market - Competitive Landscape

Key players operating in the global calciphylaxis treatment market include, 3M, Amgen Inc., BSN Medical, ConvaTec Inc., Medtronic Plc., Smith & Nephew Plc., and Laboratoris Sanifit S.L.

Calciphylaxis or calcific uremic arteriolopathy is a syndrome of vascular calcification, thrombosis, and skin necrosis. It mostly occurs in patients with end-stage kidney disease or kidney transplant. Calciphylaxis results in chronic non-healing wounds and is usually fatal. It has a high mortality rate, owing to cardiovascular disease and sepsis caused due to infected skin ulcers. The exact pathogenetic mechanisms of the disease is not known. Most patients with the condition have abnormalities in blood-clotting factors. Multiple interventions are used to treat calciphylaxis, including restoring oxygen and blood flow to the skin, decreasing calcium deposits, and intensive wound treatment.

Market Dynamics

High prevalence of kidney diseases and increasing number of clinical trials in the field of calciphylaxis treatment are major factors expected to drive growth of the calciphylaxis treatment market. According to the National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center, in 2016, the overall prevalence of chronic kidney diseases in the U.S. was around 14% of total population.

Calciphylaxis has no approved treatment, which has led to increasing number of clinical trials and research, which is expected to fuel growth of the market. For instance, in March 2015, the Multidisciplinary Calciphylaxis Program launched the first randomized trial for treatment of calciphylaxis with research focus on the role of vitamin K in the treatment of the disease.

Lack of an appropriate treatment for calciphylaxis is a major obstacle in the calciphylaxis treatment market growth. However, key players in the market are focused on identifying the root cause of the disease and its associated treatment in order to gain market share. For instance, according to a study published by the American Journal of Nephrology, in June 2018, apixaban, an anticoagulant used to treat venous thromboembolic events, can be a safe and effective alternative to warfarin in patients with End-Stage Renal Disease (ESRD) on dialysis suffering from calciphylaxis.

Key features of the study:

  • This report provides in-depth analysis of the global calciphylaxis treatment market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global calciphylaxis treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include, 3M, Amgen Inc., BSN Medical, ConvaTec Inc., Medtronic Plc., Smith & Nephew Plc., and Laboratoris Sanifit S.L.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global calciphylaxis treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for calciphylaxis treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Calciphylaxis Treatment Market, By Treatment:
    • Drug Therapy
    • Hyperbaric Oxygen Therapy
  • Global Calciphylaxis Treatment Market, By End User:
    • Hospital and Clinics
    • Homecare
    • Ambulatory Centers
  • Global Calciphylaxis Treatment Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Treatment:
        • Drug Therapy
        • Hyperbaric Oxygen Therapy
      • By End User:
        • Hospital and Clinics
        • Homecare
        • Ambulatory Centers
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Treatment:
        • Drug Therapy
        • Hyperbaric Oxygen Therapy
      • By End User:
        • Hospital and Clinics
        • Homecare
        • Ambulatory Centers
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Treatment:
        • Drug Therapy
        • Hyperbaric Oxygen Therapy
      • By End User:
        • Hospital and Clinics
        • Homecare
        • Ambulatory Centers
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Treatment:
        • Drug Therapy
        • Hyperbaric Oxygen Therapy
      • By End User:
        • Hospital and Clinics
        • Homecare
        • Ambulatory Centers
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Treatment:
        • Drug Therapy
        • Hyperbaric Oxygen Therapy
      • By End User:
        • Hospital and Clinics
        • Homecare
        • Ambulatory Centers
    • Africa
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
      • By Treatment:
        • Drug Therapy
        • Hyperbaric Oxygen Therapy
      • By End User:
        • Hospital and Clinics
        • Homecare
        • Ambulatory Centers
  • Company Profiles
    • 3M*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Amgen Inc.
    • BSN Medical
    • ConvaTec Inc.
    • Medtronic Plc.
    • Smith & Nephew Plc.
    • Laboratoris Sanifit S.L.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global calciphylaxis treatment market is estimated to surpass US$ 2,400 Million by 2026
Major players operating in the global calciphylaxis treatment market include 3M, Amgen Inc., BSN Medical, ConvaTec Inc., Medtronic Plc., Smith & Nephew Plc., and Laboratoris Sanifit S.L
Lack of an appropriate treatment for calciphylaxis is one of the major factors that is expected to hamper growth of the market over the forecast period.
Increasing clinical trials in the field of calciphylaxis is one of the major factors that is expected to propel growth of the market over the forecast period
The global calciphylaxis treatment market is estimated to exhibit a CAGR of 9.6% over the forecast period
Among regions, North America is expected hold dominant position in the market over the forecast period.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo